Precision Medicine Beyond Genomics
Open Access
- 24 May 2025
- book chapter
- Published by Springer Nature
- p. 89-110
Abstract
Precision oncology based on specific genomic alterations has become a standard in the management of some tumours. Different studies (NCI-MATCH, TAPUR, DRUP, or MyPathway) have used a broader approach, testing multiple genes at the same time and assigning targeted therapies in basket trials. These studies showed some encouraging results supporting the potential use of next-generation sequencing in precision oncology. However, the application in head and neck cancer (except for salivary gland tumours) is still limited. The field is moving quickly into other approaches such as whole genome and transcriptome analysis. Transcriptome analyses have successfully helped in treatment decisions in some patients within prospective studies (WINTHER, POG). In head and neck cancer, gene expression signatures evaluating hypoxia or predicting anti-epidermal growth factor receptor (EGFR) therapy response, have been explored. As immunotherapy has become a standard in the treatment of squamous head and neck carcinoma, ribonucleic acid (RNA)-based immune signatures have been proposed to select those patients with higher probabilities of response. All these analyses are based on bulk transcriptomics. Nevertheless, understanding the role of each cell and its spatial configuration could be useful in precision oncology. In this sense, single-cell RNA sequencing could provide a better understanding of the different cell populations and their activities and potentially predict treatment response. Other immune-related biomarkers such as the T-cell receptor characteristics could provide an improved insight into the resistance to immunotherapy in patients with head and neck cancer. Non-coding genome analysis may contribute to a better understanding of the mechanisms of resistance or sensitivity to drugs and aid in discovering new therapeutic targets. However, most of the current precision medicine approaches rely on tumour tissue. This is a limitation for a broader applicability due to tumor heterogeneity and the need for tumour biopsies. Easy-to-access biomarkers such as circulating tumour deoxyribonucleic acid (ctDNA) could overcome both limitations as well as provide a more dynamic overview of the disease. Further understanding of molecular biology and tumour microenvironment including multi-institution collaborative initiatives and prospective studies is needed to translate these findings into our clinical practice.Keywords
Funding Information
- Congresscare
This publication has 126 references indexed in Scilit:
- Metabolomics of head and neck cancer in biofluids: an integrative systematic reviewMetabolomics, 2023
- Leveraging big data of immune checkpoint blockade response identifies novel potential targetsAnnals of Oncology, 2022
- FFPE‐ATAC: A Highly Sensitive Method for Profiling Chromatin Accessibility in Formalin‐Fixed Paraffin‐Embedded SamplesCurrent Protocols, 2022
- Whole-genome and transcriptome analysis enhances precision cancer treatment optionsAnnals of Oncology, 2022
- Current Trends in Precision Medicine and Next-Generation Sequencing in Head and Neck CancerCurrent Treatment Options in Oncology, 2022
- Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 MutationJAMA Oncology, 2021
- Effect of Capivasertib in Patients With an AKT1 E17K-Mutated TumorJAMA Oncology, 2021
- Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTargeted Oncology, 2020
- Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyTargeted Oncology, 2020
- ATAC‐seq: A Method for Assaying Chromatin Accessibility Genome‐WideCurrent Protocols in Molecular Biology, 2015